Open Clinical Studies

OBSERVATIONAL STUDY FOR PEOPLE WITH NEW CONFIRMED OR SUSPECTED HIV INFECTION AFTER USE OF INJECTABLE CABOTEGRAVIR FOR HIV PREP (ACTG 5321- Group 6)

People who have used injectable cabotegravir for PREP within 90 days of a blood sample concerning for possible HIV infection will be followed in an observational study to characterize the HIV reservoir, inflammatory consequences, and viral evolution after breakthrough infection, including after ART initiation.

Participants will also be referred to the SeroPrep study:

https://seroprep.ucsf.edu/​​​​​​

Email:

[email protected] 

Call/text: (415) 806-8554

 An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons with HIV

This is a research study and your participation in this study is voluntary. The purpose of this research study is to evaluate the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and major depressive disorder that co-occurs with mild neurocognitive disorder (MND) in persons with HIV (PWH). This study will also look at whether you experience any effect on your activities of daily living.

Email:

[email protected] 

Call/text: (415) 806-8554

Eligible participants must be 18 or older, living with HIV-1, on stable HIV treatment for at least two years, have a CD4+ count of ≥200 cells/mm³, maintain an HIV viral load of <50 copies/mL for the past year, have no current Hepatitis B or C infection, and agree to use effective birth control if they can become or cause a pregnancy.

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living with HIV-1 on Suppressive Antiretroviral Therapy

This study is looking to see if an investigational anti-HIV vaccine is safe and well-tolerated in people living with HIV. The study is also trying to find out if the vaccine can help the immune system work against HIV. It is given as one injection, similar to a flu shot, in each upper arm five times over one year (ten injections total). Study participants will have a 2 in 3 chance of receiving the active vaccine and a 1 in 3 chance of getting a placebo (looks like the vaccine but contains no active medicine). A computer will assign you to one of the groups and neither you nor the study staff will know which group you are assigned to.

Email:

[email protected] 

Call/text: (415) 806-8554

A5424

To participate in the study, individuals must be living with HIV, assigned female at birth, between the ages of 40 and 60, and either in late perimenopause or early postmenopause. Participants must have been on HIV medication (ART) for over a year, not be pregnant (and agree to use contraception if at risk of pregnancy), be willing to complete a daily diary, and provide informed consent after discussion with the research team.

Menopausal Hormone Therapy for Women Living with HIV (HoT) 

This is a two-group study, where enrolled women living with Human Immunodeficiency Virus (HIV) on antiretroviral therapy (ART) will receive study medication called “Hormone replacement therapy (HT; estradiol gel with or without oral progesterone)” Or Placebo. Placebo is an inactive substance that looks the same as the treatment, like a “sugar pill”.

Email:

[email protected] 

Call/text: (415) 806-8554

Gilead Wonders

Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in
People With HIV-1 Who Are Virologically Suppressed

This study will test how safe and effective it is for people with HIV to switch from taking their daily HIV medicine (BVY) to a new once-weekly pill combination (GS-1720 and GS-4182), compared to continuing their daily BVY. Participants must have had their HIV under control with BVY for at least 24 weeks before joining the study.

Email:

[email protected] 

Call/text: (415) 806-8554

Participants must have HIV-1 with a very low or undetectable viral load at screening, a healthy immune cell count, and a strong overall white blood cell count, with the option to retest once if needed within 45 days.

They must have been on the HIV medication BIC/FTC/TAF with good viral control for at least 6 months and have no history of their treatment failing.

Past changes in medication for reasons like side effects or convenience are fine as long as they happened more than 6 months ago.

Phase 2 Study of ISL+ULO QW in Virologically Suppressed Adults With
HIV-1

The study will compare how well switching to a once-weekly treatment with ISL+ULO works versus staying on a once-daily treatment with BIC/FTC/TAF. Researchers will measure this by looking at the percentage of people whose HIV levels are still detectable (50 copies/mL or higher) after 24 weeks.

Email:

[email protected] 

Call/text: (415) 806-8554

A5394

SAFETY, TOLERABILITY, AND IMPACT OF ORAL TLR8 AGONIST SELGANTOLIMOD ON HBSAG IN PARTICIPANTS WITH BOTH CHRONIC HEPATITIS B AND HIV

This is a phase II, double-blind, randomized, placebo-controlled trial to assess safety and effectiveness of Selgantomlimod when administered orally once a week for 24 weeks, in people living with HIV and chronic hepatitis B. Selgantomlimod is an oral immunomodulator (toll-like receptor 8 agonist), given once weekly, in addition to ongoing HBV-active antiretroviral therapy.  Eligibility includes suppressed HIV and HBV viral loads, surface antigen (HBsAg) positive, on a regimen for both HIV and HBV for > 5 years, CD4 count > 350 cells/mm3, no hepatitis C or recent treatment of hepatitis C, and between 18-70 years old.  

Email:

[email protected] 

Call/text: (415) 535-9495

Harness

Phone:
628.217.6333

Email

Website

Reboot 2.0

Eligible participants use illicit opioids and have been a recipient of naloxone.

To see if you are eligible, please call us at 628.217.6325

Phone: 628.217.6325

Email

Website

PRIME

Phone: 
628.217.6319

Email

Website

M3.0

Phone:
628.217.6319

Email

Website